Biocon Ltd - Company Profile
Powered by 
All the sales intelligence you need on Biocon Ltd in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Biocon Ltd fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Biocon Ltd.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Biocon Ltd (Biocon) is a biopharmaceutical company. It focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes, and autoimmune diseases. It offers a range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics, and biosimilars, including monoclonal antibodies (MAbs), rh-Insulin, and insulin analogs. The company also provides services, including contract manufacturing, drug licensing, research, development, and manufacturing of small and large molecules for biotechnology and pharmaceutical companies globally. It has a manufacturing facility and R&D center at BioXcell, Malaysia. The company has an operational presence in the UK, Ireland, the US, Switzerland, the UAE, and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.
Headquarters
India
Address
20th Km, Hosur Road, Electronic City, Bengaluru, Karnataka, 560100
Website
www.biocon.com
Telephone
91 802 8082808
No of Employees
3,269
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
BIOCON (NSE)
Revenue (2025)
$1.9B
10.9%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
-61.9%
(2025 vs 2024)
Market Cap*
$5.9B
Net Profit Margin (2025)
XYZ
-65.7%
(2025 vs 2024)
* As of and is in US$
Biocon Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Generics: | Drug Licensing Services | Alzum Ab |
| Generic Formulations | Research and Development | RediHaler |
| Active Pharmaceutical Ingredients (APIs) | Contract Manufacturing Services | gSaxenda |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Regulatory Approval | In September, the company secured approval from the Medicines and Healthcare products Regulatory Agency for its new drug product fill-finish unit for Semglee (insulin glargine) at its insulin manufacturing facility in Malaysia. |
| 2026 | Regulatory Approval | In August, the company's subsidiary secured supplemental U.S. Food and Drug Administration approval for Yesintek 45 mg/0.5 ml single-dose prefilled autoinjector and Yesintek 90 mg/ml single-dose prefilled autoinjector. |
| 2026 | New Products/Services | In August, the company introduced Yesafili (aflibercept-jbvf) in the US. |
Competitor Comparison
| Key Parameters | Biocon Ltd | Sun Pharmaceutical Industries Ltd | Dr. Reddy's Laboratories Ltd | Cipla Ltd | Morepen Laboratories Ltd |
|---|---|---|---|---|---|
| Headquarters | India | India | India | India | India |
| City | Bengaluru | Mumbai | Hyderabad | Mumbai | Gurugram |
| State/Province | Karnataka | Maharashtra | Telangana | Maharashtra | Haryana |
| No. of Employees | 3,269 | 47,000 | 27,527 | 31,369 | 1,919 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kiran Mazumdar-Shaw | Chairman | Executive Board | 2020 | 73 |
| Shreehas Pradeep Tambe | Chief Executive Officer; Managing Director | Senior Management | 2026 | - |
| Kedar Narayan Upadhye | Chief Financial Officer | Senior Management | 2026 | - |
| Mandar Shrikant Ghatnekar | Chief Technology Officer | Senior Management | 2026 | - |
| Deepali Naair | Global Head – Brand & Corporate Communications | Senior Management | 2025 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer